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Management of portal hypertension derived from uncommon causes
Sung Hyun Kim1, Hae Min Lee1, Seung Ho Lee1, Jong Yoon Won2, and Kyung Sik Kim1
Departments of 1Hepatobiliary and Pancreatic Surgery and 2Radiology, Severance Hospital, 
Yonsei University College of Medicine, Seoul, Korea
Portal hypertension can arise from any condition interfering with normal blood flow at any level within the portal system. 
Herein, we presented two uncommon cases of the portal hypertension and its treatment with brief literature review. 
A 71-year-old man who underwent right hemihepatectomy revealed a tumor recurrence adjacent to the inferior vena 
cava (IVC). After radiofrequency ablation (RFA) with lymph node dissection, he was referred for abdominal distension. 
The abdomen computed tomography scan showed severe ascites with a narrowing middle hepatic vein (MHV) and 
IVC around the RFA site. After insertion of two stents at the IVC and MHV, the ascites disappeared. Another 
73-year-old man underwent right trisectionectomy of liver and segmental resection of the portal vein (PV). After oper-
ation, he underwent conservative management due to continuous abdominal ascites. The abdomen computed tomog-
raphy scan showed severe ascites with obliteration of the left PV. After insertion of stent, the ascites disappeared. 
A decrease of the pressure gradient between the PV and IVC is one of the important treatment strategies for portal 
hypertension. Vascular stent is useful in the reduction of pressure gradient and thus, can be a treatment option for 
portal hypertension. (Korean J Hepatobiliary Pancreat Surg 2016;20:81-84)
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INTRODUCTION
Portal hypertension is a common clinical syndrome that 
is characterized by an increased portal pressure gradient. 
It causes an increased pressure gradient between the portal 
vein (PV) and the inferior vena cava (IVC) to above nor-
mal values (1-5 mmHg). Portal hypertension causes vari-
ces within the gastrointestinal tract and can lead to gastro-
intestinal bleeding with abdominal ascites, diffuse ab-
dominal pain, diarrhea and hepatic dysfunction.1-3 Chronic 
liver disease is the most common cause of portal 
hypertension.1 However, portal hypertension has various 
rare causes.2 Herein, we presented two uncommon cases 




A 71-year-old man who underwent right hemi-
hepatectomy one year prior due to combined hep-
atocellular and cholangiocarcinoma was found with ele-
vated CA19-9 level of 60.2 U/ml at the follow-up 
examination. The imaging studies revealed tumor re-
currence in the resection margin that was adjacent to the 
inferior vena cava (IVC) with an enlarged metastatic 
lymph node (LN) at the hepatoduodenal area. We per-
formed radiofrequency ablation (RFA) with LN dissection 
due to severe adhesion between the tumor and IVC. 
Pathologic examination confirmed metastatic carcinoma 
derived from the previous cancerous lesion. Two weeks 
after discharge, he was referred to the emergency room 
for abdominal distension. Laboratory tests showed hypo-
albuminemia (2.7 g/dl) and prolonged prothrombin time 
(PT) (1.24 INR). Although the ascitic fluid was slightly 
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Fig. 1. Computed tomography of the case 1 shows the amount
of ascites with abdominal distension.
Fig. 2. Angiographic finding of 
the case 1. (A) There is a nar-
rowing IVC without hepatic 
outflow (arrowhead). (B) After 
stenting, widening of the IVC 
with outflow of hepatic vein is 
seen.
Fig. 3. Computed tomography of the case 2 shows left portal
vein thrombosis with amount of ascites (arrow).
turbid, serum-to-ascites albumin gradient was 1.3 g/dl 
suggesting transudate ascites. The abdomen computed to-
mography (CT) scan showed severe ascites with a narrow-
ing of the middle hepatic vein (MHV) and IVC around 
the RFA site (Fig. 1). The pressure gradient on IVC ve-
nography measured 11 mmHg between the IVC and MHV 
(Fig. 2A). After insertion of 2 stents at the IVC and 
MHV, the pressure gradient was decreased to 3 mmHg 
(Fig. 2B). The patient was discharged home on the fif-
teenth day with disappearance of ascites.
Case 2
A 73-year-old man underwent right trisectionectomy of 
the liver after portal vein embolization due to gallbladder 
cancer with hepatic duct invasion. Portal vein (PV) seg-
mental resection was performed intra-operatively because 
of adhesion between PV around the hilum and tumor. 
Pathologic examination confirmed chronic inflammation 
and metaplasia of gallbladder. After operation, he under-
went conservative management at the outpatient depart-
ment for several months due to continuous abdominal as-
cites and pleural effusion. Six months after the operation, 
he visited the emergency room due to melena and 
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Fig. 4. Angiographic finding of 
the case 2. (A) There is an obli-
terated left portal vein with col-
lateral formation (arrowhead). 
(B) After stenting, widening of 
the left portal vein is seen.
dizziness. Laboratory tests showed anemia (7.8 g/dl), 
thrombocytopenia (99 k/ul), hypoalbuminemia (2.2 g/dl) 
and prolonged PT (1.36 INR). Ascitic fluid was clear and 
serum-to-ascites albumin gradient was 1.9 g/dl. The abdo-
men CT scan showed severe ascites and pleural effusion 
with an oblation of the left PV (Fig. 3). Colonoscopy in-
dicated bleeding at the ascending colon. Small bowel cap-
sule endoscopy was performed to identify an accurate 
bleeding focus without success. In addition, PV stent in-
sertion was performed in order to prevent varix bleeding 
and control the portal hypertension-induced ascites and 
pleural effusion. The pressure gradient on venography 
measured 11 mmHg between the left PV and splenic vein 
(Fig. 4A). After insertion of a stent at the LPV, the pres-
sure gradient was decreased to 2 mmHg (Fig. 4B). The 
patient was discharged home on the twelfth day on recov-
ery from ascites and melena.
DISCUSSION
Portal hypertension can arise from any condition that 
interferes with normal blood flow at any level within the 
portal system.1-3 Among these, hepatic venous outflow ob-
struction that is called Budd-Chiari syndrome (BCS) ac-
counts for 5-10% of portal hypertension.4,5 BCS is classi-
fied as primary or secondary BCS. Primary BCS occurs 
due to intrinsic intraluminal thrombosis or webs and sec-
ondary BCS occurs due to intraluminal invasion or extra-
luminal compression.4 Hepatic vein occlusion after radio-
frequency ablation is classified as secondary BCS and its 
incidence is very rare. Hepatic vein occlusion occurs by 
liver parenchymal deformity due to hepatic infarction. 
However, the reported incidence of hepatic infarction after 
RFA is only 0.1%.6 Moreover, because of the heat-sink 
effect that is due to the adjacent hepatic vessels, hepatic 
infarction rarely occurs around hepatic vein.7
Portal venous stenosis by extrahepatic obstruction ac-
counts for 5-10% of portal hypertension.8 Increasing liver 
transplantation has led to frequent cases of acquired portal 
vein stenosis post-transplantation.9 In the non-transplant 
population, PV stenosis occurs rarely due to tumor en-
casement or post-surgical complications.10 While PV 
stenosis was manifested in advanced pancreatic and bili-
ary neoplasms a decade ago, it currently presents as 
post-surgical complications.10,11 
Although portal hypertension is derived from different 
causes, it causes similar and typical symptoms such as as-
cites, varix or gastrointestinal bleeding. The study of por-
tal hypertension during the past decades has dramatically 
changed our knowledge of it. Recently, portal pressure 
gradient has received attention as the complications of 
portal hypertension.12 According to causes of portal hyper-
tension, different pressure changes are seen between de-
tailed areas such as intrasplenic pressure, portal vein pres-
sure or right atrial pressure. However, all of them increase 
the portal pressure gradient and can cause the complica-
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tions of portal hypertension.1-3 The critical threshold value 
of portal pressure gradient is 10 mmHg. In other words, 
if the portal pressure gradient can be controlled at less 
than 10 mmHg, all complications of portal hypertension 
can be prevented.
In accordance with this trend, several studies have used 
insertion of vascular stent to resolve blockage of the por-
tal blood flow and improve symptoms. Although there is 
no large scale study of usefulness of stent insertion for 
portal hypertension, previous reports indicated good clin-
ical outcome at various sites from PV to IVC by various 
causes of portal hypertension.10,13-15 In our cases, the por-
tal pressure gradient was more than 10 mmHg before the 
procedure and decreased to below 5 mmHg after the 
procedure. After control of portal pressure gradient, com-
plications of portal hypertension i.e., ascites, pleural effu-
sion and gastrointestinal bleeding from unknown focus 
disappeared.
There is currently no consensus on prophylactic anti-
coagulation therapy for maintaining stent patency after its 
insertion for portal hypertension. Some recommend at 
least 6 month interval follow-ups for clinical and labo-
ratory evaluations.2 Our patients were treated with warfar-
in and evaluated for stent patency using abdomen CT 
scans every 3 months; consequently, the first stent has 
been patent for 8 months and the other stent for 6 months.
In conclusion, regardless of the causes, a decrease of 
the pressure gradient between the PV and the IVC is one 
of the important treatment strategies of portal 
hypertension. Vascular stent is useful to reduce the portal 
pressure gradient and thus, can be a treatment option for 
portal hypertension.
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